NYSE:ZYME - Zymeworks Stock Price, Price Target & More

$13.14 +0.78 (+6.31 %)
(As of 04/26/2018 01:37 AM ET)
Previous Close$12.36
Today's Range$12.32 - $13.35
52-Week Range$6.25 - $14.25
Volume77,774 shs
Average Volume26,417 shs
Market Capitalization$309.10 million
P/E Ratio-23.05
Dividend YieldN/A
BetaN/A

About Zymeworks (NYSE:ZYME)

Zymeworks logoZymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:ZYME
CUSIPN/A
Phone604-678-1388

Debt

Debt-to-Equity RatioN/A
Current Ratio6.30%
Quick Ratio6.30%

Price-To-Earnings

Trailing P/E Ratio-23.05
Forward P/E Ratio-5.30
P/E GrowthN/A

Sales & Book Value

Annual Sales$51.76 million
Price / Sales6.46
Cash FlowN/A
Price / CashN/A
Book Value$4.59 per share
Price / Book2.86

Profitability

EPS (Most Recent Fiscal Year)($0.57)
Net Income$-10,400,000.00
Net Margins-20.10%
Return on Equity-12.37%
Return on Assets-8.32%

Miscellaneous

Employees147
Outstanding Shares25,460,000

How to Become a New Pot Stock Millionaire

Zymeworks (NYSE:ZYME) Frequently Asked Questions

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

How were Zymeworks' earnings last quarter?

Zymeworks (NYSE:ZYME) released its quarterly earnings data on Wednesday, March, 14th. The company reported $1.28 earnings per share for the quarter. The company had revenue of $50.07 million for the quarter. Zymeworks had a negative return on equity of 12.37% and a negative net margin of 20.10%. View Zymeworks' Earnings History.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release their next quarterly earnings announcement on Monday, May, 21st 2018. View Earnings Estimates for Zymeworks.

What price target have analysts set for ZYME?

6 brokerages have issued 1-year price objectives for Zymeworks' shares. Their forecasts range from $8.00 to $20.00. On average, they anticipate Zymeworks' share price to reach $16.40 in the next year. View Analyst Ratings for Zymeworks.

Who are some of Zymeworks' key competitors?

Who are Zymeworks' key executives?

Zymeworks' management team includes the folowing people:
  • Dr. Ali Tehrani Ph.D., Co-Founder, Chief Exec. Officer, Pres and Director (Age 46)
  • Mr. Neil Klompas CPA, CA, Chief Financial Officer (Age 46)
  • Dr. Diana F. Hausman M.D., Chief Medical Officer (Age 55)
  • Dr. Donald L. Drakeman Ph.D., J.D., Special Advisor (Age 64)
  • Mr. David Tucker, Chief Operating Officer

When did Zymeworks IPO?

(ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

Has Zymeworks been receiving favorable news coverage?

Press coverage about ZYME stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zymeworks earned a news impact score of 0.09 on Accern's scale. They also gave news headlines about the company an impact score of 44.63 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $13.14.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $309.10 million and generates $51.76 million in revenue each year. The company earns $-10,400,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Zymeworks employs 147 workers across the globe.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 West 8th Avenue Suite 540, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]


MarketBeat Community Rating for Zymeworks (ZYME)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  132
MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe ZYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYME will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zymeworks (NYSE:ZYME) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Zymeworks in the last 12 months. Their average twelve-month price target is $16.40, suggesting that the stock has a possible upside of 24.81%. The high price target for ZYME is $20.00 and the low price target for ZYME is $8.00. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.602.60
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.40$16.40$16.00$16.00
Price Target Upside: 24.81% upside38.28% upside100.50% upside100.50% upside

Zymeworks (NYSE:ZYME) Consensus Price Target History

Price Target History for Zymeworks (NYSE:ZYME)

Zymeworks (NYSE:ZYME) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018Raymond JamesInitiated CoverageOutperform -> Outperform$18.00LowView Rating Details
9/30/2017CormarkReiterated RatingBuyMediumView Rating Details
9/7/2017BarclaysReiterated RatingOverweight -> Underweight$8.00HighView Rating Details
5/23/2017CitigroupInitiated CoverageBuy -> Buy$18.00LowView Rating Details
5/23/2017Wells FargoInitiated CoverageOutperform -> Outperform$20.00LowView Rating Details
5/23/2017Canaccord GenuityInitiated CoverageBuy -> Buy$18.00LowView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Zymeworks (NYSE:ZYME) Earnings History and Estimates Chart

Earnings by Quarter for Zymeworks (NYSE:ZYME)

Zymeworks (NYSE:ZYME) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.48 EPS
Next Year EPS Consensus Estimate: $-1.75 EPS

Zymeworks (NYSE ZYME) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/21/2018        
3/14/2018Q4 2017$1.28$50.07 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.74)($0.65)$0.12 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.62)($0.63)$1.34 millionViewN/AView Earnings Details
5/15/2017Q1($1.13)$0.23 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Zymeworks (NYSE:ZYME) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Zymeworks (NYSE ZYME) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 7.27%
Insider Trading History for Zymeworks (NYSE:ZYME)
Institutional Ownership by Quarter for Zymeworks (NYSE:ZYME)

Zymeworks (NYSE ZYME) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Zymeworks (NYSE ZYME) News Headlines

Source:
DateHeadline
Zymeworks (ZYME) Announces Expanded Bispecific Antibody Collaboration with Celgene Corp. (CELG)Zymeworks (ZYME) Announces Expanded Bispecific Antibody Collaboration with Celgene Corp. (CELG)
www.streetinsider.com - April 25 at 9:12 AM
Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual MeetingZymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - April 25 at 9:12 AM
BRIEF-Zymeworks And Celgene Expand Bispecific Antibody CollaborationBRIEF-Zymeworks And Celgene Expand Bispecific Antibody Collaboration
www.reuters.com - April 24 at 9:07 AM
Zymeworks up 15% after hours on expanded Celgene partnershipZymeworks up 15% after hours on expanded Celgene partnership
seekingalpha.com - April 23 at 4:38 PM
Zymeworks and Celgene Expand Bispecific Antibody CollaborationZymeworks and Celgene Expand Bispecific Antibody Collaboration
finance.yahoo.com - April 23 at 4:38 PM
Zymeworks (ZYME) Receives Consensus Rating of "Buy" from BrokeragesZymeworks (ZYME) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 20 at 5:25 AM
-$0.68 EPS Expected for Zymeworks Inc (ZYME) This Quarter-$0.68 EPS Expected for Zymeworks Inc (ZYME) This Quarter
www.americanbankingnews.com - April 11 at 5:17 AM
Want to Beat the TSX? Buy These 3 Stocks Poised for Monster Long-Term GrowthWant to Beat the TSX? Buy These 3 Stocks Poised for Monster Long-Term Growth
www.msn.com - April 5 at 4:39 PM
Was Zymeworks Inc’s (TSE:ZYME) Earnings Growth Better Than The Industry’s?Was Zymeworks Inc’s (TSE:ZYME) Earnings Growth Better Than The Industry’s?
finance.yahoo.com - April 3 at 4:43 PM
3 Drug and Nutrition Stocks That Belong in Your TFSA3 Drug and Nutrition Stocks That Belong in Your TFSA
www.fool.ca - March 26 at 4:33 PM
Zymeworks Inc (ZYME) Given Average Rating of "Buy" by BrokeragesZymeworks Inc (ZYME) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 26 at 5:41 AM
Zymeworks Inc (ZYME) Expected to Post Earnings of -$0.68 Per ShareZymeworks Inc (ZYME) Expected to Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - March 25 at 8:48 AM
Raymond James Financial Begins Coverage on Zymeworks (ZYME)Raymond James Financial Begins Coverage on Zymeworks (ZYME)
www.americanbankingnews.com - March 19 at 11:10 AM
BRIEF-Zymeworks Reports Qtrly Net Income Per Common Share $1.29BRIEF-Zymeworks Reports Qtrly Net Income Per Common Share $1.29
www.reuters.com - March 14 at 6:03 PM
Zymeworks Reports 2017 Year-End Financial ResultsZymeworks Reports 2017 Year-End Financial Results
finance.yahoo.com - March 14 at 6:03 PM
Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos AcquisitionZymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition
finance.yahoo.com - March 14 at 6:03 PM
Zymeworks to Present at Barclays 2018 Global Healthcare ConferenceZymeworks to Present at Barclays 2018 Global Healthcare Conference
finance.yahoo.com - March 7 at 5:32 PM
Zymeworks Inc (ZYME) Receives Consensus Recommendation of "Buy" from AnalystsZymeworks Inc (ZYME) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 1 at 5:30 AM
Zymeworks Opening Clinical Sites in CanadaZymeworks Opening Clinical Sites in Canada
finance.yahoo.com - February 28 at 5:14 PM
BRIEF-BDC Capital Reports 7.58 Pct Passive Stake In ZymeworksBRIEF-BDC Capital Reports 7.58 Pct Passive Stake In Zymeworks
www.reuters.com - February 14 at 4:57 PM
Critical Contrast: Zymeworks (ZYME) & The CompetitionCritical Contrast: Zymeworks (ZYME) & The Competition
www.americanbankingnews.com - February 7 at 1:12 AM
Zymeworks Inc (ZYME) Given Consensus Rating of "Hold" by BrokeragesZymeworks Inc (ZYME) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 4 at 11:14 AM
Zymeworks Inc (ZYME) Expected to Post Earnings of -$0.62 Per ShareZymeworks Inc (ZYME) Expected to Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - February 2 at 8:44 AM
Contrasting Zymeworks (ZYME) and Its CompetitorsContrasting Zymeworks (ZYME) and Its Competitors
www.americanbankingnews.com - January 17 at 3:12 AM
-$0.62 Earnings Per Share Expected for Zymeworks Inc (ZYME) This Quarter-$0.62 Earnings Per Share Expected for Zymeworks Inc (ZYME) This Quarter
www.americanbankingnews.com - January 16 at 9:30 AM
Zymeworks (ZYME) Rating Lowered to Hold at Zacks Investment ResearchZymeworks (ZYME) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 13 at 4:08 PM
Financial Survey: Verastem (VSTM) and Zymeworks (ZYME)Financial Survey: Verastem (VSTM) and Zymeworks (ZYME)
www.americanbankingnews.com - January 12 at 8:18 AM
Zymeworks Inc (ZYME) Receives Consensus Recommendation of "Hold" from AnalystsZymeworks Inc (ZYME) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 10 at 8:14 AM
Critical Analysis: Zymeworks (ZYME) and The CompetitionCritical Analysis: Zymeworks (ZYME) and The Competition
www.americanbankingnews.com - January 9 at 5:10 AM
Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 PrioritiesZymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities
finance.yahoo.com - January 7 at 7:37 PM
Zymeworks Inc (ZYME) Given Average Rating of "Hold" by AnalystsZymeworks Inc (ZYME) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - December 16 at 8:46 AM
Applied BioMath, LLC to Sponsor and Present at PepTalk: The Protein Science WeekApplied BioMath, LLC to Sponsor and Present at PepTalk: The Protein Science Week
www.prnewswire.com - December 12 at 6:18 PM
Head-To-Head Survey: Affimed (AFMD) & Zymeworks (ZYME)Head-To-Head Survey: Affimed (AFMD) & Zymeworks (ZYME)
www.americanbankingnews.com - November 28 at 5:46 PM
Zymeworks Inc. (ZYME) Receives Average Recommendation of "Hold" from BrokeragesZymeworks Inc. (ZYME) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 21 at 8:24 AM

SEC Filings

Zymeworks (NYSE:ZYME) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zymeworks (NYSE:ZYME) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zymeworks (NYSE ZYME) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.